Chunyang Jin

Chunyang Jin

Auto-generated profile, based on publicly available information

Chunyang Jin

Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina 27709, United States

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2015 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
DWDavid Westover
David Westover
XLXiang Ling
Xiang Ling
HLHong Lam
Hong Lam
JWJacob Welch
Jacob Welch
CJChunyang Jin
Chunyang Jin
Fengzhi LiFengzhi Li
Fengzhi Li
Irinotecan is a camptothecin analogue currently used in clinical practice to treat advanced colorectal cancer. However, acquired resistance mediated by the drug efflux pump ABCG2 is a recognized problem. We reported on a novel camptothecin analogue, FL118, which shows anticancer activity superior to irinotecan. In this study, we sought to investigate the potency of FL118 versus irinotecan or its active metabolite, SN-38, in both in vitro and in vivo models of human cancer with high ABCG2 activity. We also sought to assess the potency and ABCG2 affinity of several FL118 analogues with B-ring substitutions. Colon and lung cancer cells with and without ABCG2 overexpression were treated with FL118 in the presence and absence of Ko143, an ABCG2-selective inhibitor, or alternatively by genetically modulating ABCG2 expression. Using two distinct in vivo human tumor animal models, we further assessed whether FL118 could extend time to progression in comparison with irinotecan. Lastly, we investigated a series of FL118 analogues with B-ring substitutions for ABCG2 sensitivity. Both pharmacological inhibition and genetic modulation of ABCG2 demonstrated that, in contrast to SN-38, FL118 was able to bypass ABCG2-mediated drug resistance. FL118 also extended time to progression in both in vivo models by more than 50% compared with irinotecan. Lastly, we observed that FL118 analogues with polar substitutions had higher affinity for ABCG2, suggesting that the nonpolar nature of FL118 plays a role in bypassing ABCG2-mediated resistance. Our results suggest that in contrast to SN-38 and topotecan, FL118 is a poor substrate for ABCG2 and can effectively overcome ABCG2-mediated drug resistance. Our findings expand the uniqueness of FL118 and support continued development of FL118 as an attractive therapeutic option for patients with drug-refractory cancers resulting from high expression of ABCG2.

2 May 2014 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
CJChunyang Jin
Chunyang Jin
ADAnn M. Decker
Ann M. Decker
XHXi-Ping Huang
Xi-Ping Huang
BGBrian P. Gilmour
Brian P. Gilmour
BBBruce E. Blough
Bruce E. Blough
XZX. Peter Zhang
X. Peter Zhang
GPR88 is an orphan G-protein-coupled receptor (GPCR) enriched in the striatum. Genetic deletion and gene expression studies have suggested that GPR88 plays an important role in the regulation of striatal functions and is implicated in psychiatric disorders. The signal transduction pathway and receptor functions of GPR88, however, are still largely unknown due to the lack of endogenous and synthetic ligands. In this paper, we report the synthesis of a GPR88 agonist 2-PCCA and its pure diastereomers, which were functionally characterized in both transiently and stably expressing GPR88 HEK293 cells. 2-PCCA inhibited isoproterenol-stimulated cAMP accumulation in a concentration-dependent manner in cells expressing GPR88 but not in the control cells, suggesting that the observed cAMP inhibition is mediated through GPR88 and that GPR88 is coupled to Gαi. 2-PCCA did not induce calcium mobilization in GPR88 cells, indicating no Gαq-mediated response. A structure–activity relationship (SAR) study of 2-PCCA was also conducted to explore the key structural features for GPR88 agonist activity.

16 May 2016 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
LJLulu Jiang
Lulu Jiang
XWXuefei Wu
Xuefei Wu
SWShuo Wang
Shuo Wang
SCShih-Heng Chen
Shih-Heng Chen
HZHui Zhou
Hui Zhou
JHJau-shyong Hong
Jau-shyong Hong
Clozapine, an atypical antipsychotic medication, has been effectively used to treat refractory schizophrenia. However, the clinical usage of clozapine is limited due to a high incidence of neutropenia or agranulocytosis. We previously reported that clozapine protected dopaminergic neurons through inhibition of microglial activation. The purpose of this study was to explore the neuroprotective effects of clozapine metabolites clozapine N-oxide (CNO) and N-desmethylclozapine (NDC), as well as their propensity to cause neutropenia. The primary midbrain neuron-glia culture was applied to detect the neuroprotective and anti-inflammatory effect of clozapine and its metabolites in lipopolysaccharide (LPS) and MPP+-induced toxicity. And the subsequent mechanism was demonstrated by gp91 phox mutant cell cultures as well as microgliosis cell lines. In vivo, to confirm the neuroprotective effect of clozapine and CNO, we measured the dopaminergic neuronal loss and rotarod motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-generated mouse Parkinson’s disease (PD) model. The neutropenia or agranulocytosis of clozapine and its metabolites was illustrated by white blood cell count of the treated mice. We found that, in midbrain neuron-glia cultures, CNO and NDC were more potent than clozapine in protecting dopaminergic neurons against LPS and MPP+-induced toxicity. CNO and NDC-afforded neuroprotection was linked to inhibition of microglia-mediated neuroinflammation, as demonstrated by abolished neuroprotection in microglia-depleted cultures and their capacity of inhibiting LPS-induced release of proinflammatory factors from activated microglia. NADPH oxidase (NOX2) was subsequently recognized as the main target of CNO and NDC since genetic ablation of gp91 phox , the catalytic subunit of NOX2, abolished their neuroprotective effects. CNO and NDC inhibited NOX2 activation through interfering with the membrane translocation of the NOX2 cytosolic subunit, p47 phox . The neuroprotective effects of CNO were further verified in vivo as shown by attenuation of dopaminergic neurodegeneration, motor deficits, and reactive microgliosis in MPTP-generated mouse PD model. More importantly, unlike clozapine, CNO did not lower the white blood cell count. Altogether, our results show that clozapine metabolites elicited neuroprotection through inactivation of microglia by inhibiting NOX2. The robust neuroprotective effects and lack of neutropenia suggest that clozapine metabolites may be promising candidates for potential therapy for neurodegenerative diseases.

16 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CJChunyang Jin
Chunyang Jin
ADAnn M. Decker
Ann M. Decker
VMViren H. Makhijani
Viren H. Makhijani
JBJoyce Besheer
Joyce Besheer
EDEmmanuel Darcq
Emmanuel Darcq
RMRangan Maitra
Rangan Maitra

17 April 2007 in Organic Letters
Verified
Journal Article
Closed access
CJChunyang Jin
Chunyang Jin
JBJason P. Burgess
Jason P. Burgess
JKJohn A. Kepler
John A. Kepler
CCC. Edgar Cook
C. Edgar Cook

14 August 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LZLiqin Zhao
Liqin Zhao
CJChunyang Jin
Chunyang Jin
ZMZisu Mao
Zisu Mao
MGMadathil B. Gopinathan
Madathil B. Gopinathan
KRKenneth Rehder
Kenneth Rehder
RBRoberta D. Brinton
Roberta D. Brinton